G2TT
来源类型Working Paper
规范类型报告
DOI10.3386/w14932
来源IDWorking Paper 14932
What's the \"Interest\" in FDA Drug Advisory Committee Conflicts of Interest?
Joseph Golec; John Vernon
发表日期2009-04-30
出版年2009
语种英语
摘要Food and Drug Administration (FDA) drug advisory committee members sometimes have financial interests tied to drug companies. Congress and the public have become concerned that these financial interests lead to conflicts of interest. They conclude that the conflicts bias committee recommendations, and lead to unsafe or ineffective drugs being approved for public consumption, or, conversely, delays in approval of safe and effective drugs. Our paper provides empirical evidence, based on an event study methodology, that advisory committee meetings lead to weak or statistically insignificant effects on stock prices and hence equity values of regulated companies assumed to be affected by the particular matters coming before committee meetings.
主题Financial Economics ; Financial Markets ; Corporate Finance ; Health, Education, and Welfare ; Health ; Education
URLhttps://www.nber.org/papers/w14932
来源智库National Bureau of Economic Research (United States)
引用统计
资源类型智库出版物
条目标识符http://119.78.100.153/handle/2XGU8XDN/572608
推荐引用方式
GB/T 7714
Joseph Golec,John Vernon. What's the \"Interest\" in FDA Drug Advisory Committee Conflicts of Interest?. 2009.
条目包含的文件
文件名称/大小 资源类型 版本类型 开放类型 使用许可
w14932.pdf(121KB)智库出版物 限制开放CC BY-NC-SA浏览
个性服务
推荐该条目
保存到收藏夹
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Joseph Golec]的文章
[John Vernon]的文章
百度学术
百度学术中相似的文章
[Joseph Golec]的文章
[John Vernon]的文章
必应学术
必应学术中相似的文章
[Joseph Golec]的文章
[John Vernon]的文章
相关权益政策
暂无数据
收藏/分享
文件名: w14932.pdf
格式: Adobe PDF
此文件暂不支持浏览

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。